Drugs / SB414
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03431610 | Nov 2017 → May 2018 | atopic eczema | Novan, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03445013 | Oct 2017 → Jan 2018 | psoriasis | Novan, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SB414 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03431610 ↗ |
| Route | Topical | “SB414 2% topically twice daily” NCT03431610 ↗ |